

Omalizumab

Reduce direct handling to a minimum and wear appropriate personal protective equipment		
Omalizumab dosing may be weight based; ensure accuracy of documented weight before administration		
Form & Storage	Xolair®: Pre-filled syringe containing 75mg/mL and 150mg/mL solution for Injection Olmyclo™: 75mg/mL and 150mg/mL solution for injection in pre-filled pen	Store in a fridge at 2°C - 8°C in original packaging to protect from light
Reconstitution	Already in solution	
Administration	For subcutaneous administration only - The syringe should be taken out of the refrigerator 30 minutes before injecting to allow it to reach room temperature. - Doses of more than 150 mg should be divided across two or more injection sites. - The injections are administered subcutaneously in the deltoid region of the arm. Alternatively, the injections can be administered in the thigh if there is any reason precluding administration in the deltoid region.	
Monitoring	- Pre and post injection vital signs - Local or systemic allergic reactions, including anaphylaxis and anaphylactic shock, may occur when taking omalizumab, also with onset after a long duration of treatment. Most of these reactions occurred within 2 hours after the first and subsequent injections of Xolair but some started beyond 2 hours and even beyond 24 hours after the injection. - For the first three injections, the patient is monitored in the infusion unit for two hours - For subsequent injections, the monitoring period should be 20 minutes Blood tests including FBC, U/E and LFTs monthly before first 3 doses by GP/phlebotomy, thereafter every three months by GP/Phlebotomy - Once the patient is established on this treatment (more than three doses), subsequent injections may be given in the asthma out patient's clinic - If the patient presents to the unit and meets the criteria in 7.7*, medical review may be required prior to administration of this medication	
Documentation Requirements	Document batch numbers and expiry dates of vials in medical notes.	
Additional Information	*See PPG-CUH-CUH-243 Policy Procedure and Guidelines for Management of Patients Attending CUH Infusion Unit for Intravenous Therapy CUH for more information ³	

Information provided relates to Xolair® (Novartis) Olmyclo (Celltrion) last updated 9/7/26